Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Combination therapy before surgery improves outcomes for patients with HER2 positive breast cancer

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.04.16
Views: 4038

Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA

Dr Angela deMichele speaks with ecancertv at AACR 2016 about the results of the ISPY2 trial to determine new drug therapies for patients with HER2 positive breast cancer.

From this arm, she reports significant improvement among patients receiving TDM1 with pertuzumab compared to current therapies.

With this success in mind, she discusses the novel design of the ISPY2 trial, which accelerates patients towards more successful schemes to improve drug design and reduce toxicity, and its possible applications across the sector.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation